Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 14/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779272 | 1.00 | KEAP1 (0.54) | KEAP1NFE2L2CYP11B1CYP11B2DHODH | |
| SCHEMBL5779276 | 1.00 | KEAP1 (0.54) | KEAP1NFE2L2CYP11B1CYP11B2DHODH | |
| SCHEMBL6605286 | 0.84 | KEAP1 (0.36) | KEAP1NFE2L2CYP11B1CYP11B2 | |
| SCHEMBL6605291 | 0.84 | KEAP1 (0.36) | KEAP1NFE2L2CYP11B1CYP11B2 | |
| SCHEMBL9562369 | 0.83 | KEAP1 (0.44) | KEAP1NFE2L2CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL31696352 | 0.83 | KEAP1 (0.44) | KEAP1NFE2L2CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL9776049 | 0.83 | KEAP1 (0.35) | KEAP1NFE2L2CYP11B1CYP11B2NPC1 | |
| SCHEMBL13756506 | 0.83 | KEAP1 (0.44) | KEAP1NFE2L2CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL9776053 | 0.83 | KEAP1 (0.35) | KEAP1NFE2L2CYP11B1CYP11B2NPC1 | |
| SCHEMBL6607388 | 0.82 | KEAP1 (0.35) | KEAP1NFE2L2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2025-10-09 | — | — | US | disclosed |
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2025-07-01 | — | — | US | disclosed |
| EP-3983078-B1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2023-11-15 | — | — | EP | disclosed |
| US-20220251082-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-08-11 | — | — | US | disclosed |
| EP-3983078-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020249773-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251082-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | KEAP1 471/4885NFE2L2 76/4885CYP11B1 41/4885 |
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | KEAP1 471/4885NFE2L2 76/4885CYP11B1 41/4885 |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | KEAP1 471/4885NFE2L2 76/4885CYP11B1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.